| Title |
Preclinical validation of interleukin 6 as a therapeutic target in multiple myeloma
|
|---|---|
| Published in |
Immunologic Research, May 2014
|
| DOI | 10.1007/s12026-014-8528-x |
| Pubmed ID | |
| Authors |
Timothy R. Rosean, Van S. Tompkins, Guido Tricot, Carol J. Holman, Alicia K. Olivier, Fenghuang Zhan, Siegfried Janz |
| Abstract |
Studies on the biologic and molecular genetic underpinnings of multiple myeloma (MM) have identified the pleiotropic, pro-inflammatory cytokine, interleukin-6 (IL-6), as a factor crucial to the growth, proliferation and survival of myeloma cells. IL-6 is also a potent stimulator of osteoclastogenesis and a sculptor of the tumor microenvironment in the bone marrow of patients with myeloma. This knowledge has engendered considerable interest in targeting IL-6 for therapeutic purposes, using a variety of antibody- and small-molecule-based therapies. However, despite the early recognition of the importance of IL-6 for myeloma and the steady progress in our knowledge of IL-6 in normal and malignant development of plasma cells, additional efforts will be required to translate the promise of IL-6 as a target for new myeloma therapies into significant clinical benefits for patients with myeloma. This review summarizes published research on the role of IL-6 in myeloma development and describes ongoing efforts by the University of Iowa Myeloma Multidisciplinary Oncology Group to develop new approaches to the design and testing of IL-6-targeted therapies and preventions of MM. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 59 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Germany | 1 | 2% |
| Australia | 1 | 2% |
| Unknown | 57 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 13 | 22% |
| Other | 7 | 12% |
| Student > Bachelor | 6 | 10% |
| Researcher | 6 | 10% |
| Student > Doctoral Student | 3 | 5% |
| Other | 7 | 12% |
| Unknown | 17 | 29% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 14 | 24% |
| Biochemistry, Genetics and Molecular Biology | 10 | 17% |
| Agricultural and Biological Sciences | 6 | 10% |
| Nursing and Health Professions | 2 | 3% |
| Immunology and Microbiology | 2 | 3% |
| Other | 6 | 10% |
| Unknown | 19 | 32% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 August 2014.
All research outputs
#18,375,478
of 22,759,618 outputs
Outputs from Immunologic Research
#663
of 901 outputs
Outputs of similar age
#163,050
of 226,346 outputs
Outputs of similar age from Immunologic Research
#26
of 33 outputs
Altmetric has tracked 22,759,618 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 901 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.0. This one is in the 16th percentile – i.e., 16% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 226,346 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 15th percentile – i.e., 15% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 33 others from the same source and published within six weeks on either side of this one. This one is in the 12th percentile – i.e., 12% of its contemporaries scored the same or lower than it.